Here's a few additional thoughts on KNDL. . . .
I believe that biotech is going to be the next big wave in the stock market in the coming years (like Internet stocks are today). Thus, I've been looking for a smart way to ride that wave.
I'm generally familiar with contract laboratories like KNDL because I work with a number of similar laboratories that evaluate health and safety issues associated with pesticides (my area of legal expertise). (However, I have not worked with KNDL and I have no specific knowledge about KNDL other than what's publicly available).
As part of my legal work, I also am very familiar with what's happening in the argi-chem industry, which is being revolutionized by biotech. I understand this also is happening in the pharmaceutical industry, although I don't have first hand knowledge like I do with agri-chem.
Due to exploding research requirements, primary pharmaceutical and agri-chem companies often find it is more cost effective to contract their work out to laboratories like KNDL. Thus, KNDL potentially is a low-risk, high-return way to invest in biotech without having to take the high risk of trying to figure out which primary pharmaceutical or agri-chem companies are ultimately going to make it to market with blockbuster products.
Bottomline: Work is going to be sent to laboratories like KNDL regardless of the success or failure of individual pharmaceutical and agri-chem companies. Thus, KNDL is a low-risk way to buy into the emerging high growth biotech sector and ride that sector to increased profits.
Anyway, that's my opinion.
Finally, I'm not trying to be a cheerleader for KNDL, and I value any contrary facts or opinions. After all, we're all motivated by the same goal -- maximum returns on our investments.
-- Jim |
